Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- digoxin
- Xopenex (levalbuterol)
Interactions between your drugs
digoxin levalbuterol
Applies to: digoxin, Xopenex (levalbuterol)
MONITOR: Coadministration with albuterol decreases digoxin's serum concentration. The mechanism of action may involve an albuterol-induced increased distribution of digoxin to skeletal muscle. In a pharmacokinetic study, ten healthy patients were administered digoxin 0.5 mg daily for 10 days and then they were administered a single 3 mg or 4 mg oral dose of albuterol. This study reported a 22% decrease in serum digoxin levels and a 14% decrease in serum potassium after the albuterol dose. In addition, the effects of hypokalemia caused by beta-2 agonists such as albuterol may lead to an increased risk of digitalis induced arrhythmias. The clinical significance for patients who are receiving albuterol inhalation and digoxin is unclear.
MANAGEMENT: Caution is advised if albuterol is used concomitantly with digoxin. Monitoring of serum digoxin and potassium concentrations may be required. Clinical monitoring for digoxin toxicity and/or hypokalemia, particularly in patients at risk of hypokalemia should also be considered. Dosage adjustments for either medication may also be required whenever digoxin and albuterol are used concurrently. Patients should be advised to seek immediate medical attention if they experience signs of arrhythmias, such as sudden dizziness, lightheadedness, fainting, shortness of breath, or irregular heartbeats.
References (8)
- Edner M, Jogestrand T, Dahlqvist R (1992) "Effect of salbutamol on digoxin pharmacokinetics." Eur J Clin Pharmacol, 42, p. 197-201
- Edner M, Jogestrand T (1990) "Oral salbutamol decreases serum digoxin concentration." Eur J Clin Pharmacol, 38, p. 195-7
- (2002) "Product Information. Proventil (albuterol)." Schering Corporation
- (2002) "Product Information. Ventolin (albuterol)." Glaxo Wellcome
- (2001) "Product Information. Xopenex (levalbuterol)." Sepracor Inc
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
- Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
Drug and food interactions
digoxin food
Applies to: digoxin
Administration of digoxin with a high-fiber meal has been shown to decrease its bioavailability by almost 20%. Fiber can sequester up to 45% of the drug when given orally. Patients should be advised to maintain a regular diet without significant fluctuation in fiber intake while digoxin is being titrated.
Grapefruit juice may modestly increase the plasma concentrations of digoxin. The mechanism is increased absorption of digoxin due to mild inhibition of intestinal P-glycoprotein by certain compounds present in grapefruits. In 12 healthy volunteers, administration of grapefruit juice with and 30 minutes before, as well as 3.5, 7.5, and 11.5 hours after a single digoxin dose (0.5 mg) increased the mean area under the plasma concentration-time curve (AUC) of digoxin by just 9% compared to administration with water. Moreover, P-glycoprotein genetic polymorphism does not appear to influence the magnitude of the effects of grapefruit juice on digoxin. Thus, the interaction is unlikely to be of clinical significance.
References (2)
- Darcy PF (1995) "Nutrient-drug interactions." Adverse Drug React Toxicol Rev, 14, p. 233-54
- Becquemont L, Verstuyft C, Kerb R, et al. (2001) "Effect of grapefruit juice on digoxin pharmacokinetics in humans." Clin Pharmacol Ther, 70, p. 311-6
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Jardiance
Jardiance (empagliflozin) is used to treat type 2 diabetes, chronic kidney disease and reduce the ...
Farxiga
Farxiga (dapagliflozin) is an oral prescription medication that may be given to certain adults with ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Lasix
Lasix is a loop diuretic used to treat fluid retention from heart, liver, or kidney conditions, and ...
Xarelto
Xarelto (rivaroxaban) is a factor Xa inhibitor used to reduce the risk of blood clots and stroke in ...
Entresto
Entresto is an oral combination heart medication that contains two blood pressure-lowering ...
Coreg
Coreg (carvedilol) is used to treat heart failure and hypertension (high blood pressure). Includes ...
Coumadin
Coumadin is used to prevent heart attacks, strokes, and blood clots in veins and arteries. Learn ...
Aldactone
Aldactone (spironolactone) is used to diagnose or treat a condition in which you have too much ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.